Go Pro
NASDAQ:ISPC

iSpecimen Q1 2025 Earnings Report

iSpecimen logo
$1.26 +0.01 (+0.80%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$1.22 -0.04 (-3.10%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iSpecimen EPS Results

Actual EPS
-$28.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

iSpecimen Revenue Results

Actual Revenue
$1.06 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iSpecimen Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Sunday, May 18, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

iSpecimen's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules

Earnings Documents

iSpecimen Earnings Headlines

Reviewing VivoSim Labs (NASDAQ:VIVS) and iSpecimen (NASDAQ:ISPC)
Elon’s AI Phone is coming
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
iSpecimen to Acquire Foldlab AI Disease Analytics
iSpecimen Engages IR Agency for Investor Marketing
See More iSpecimen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iSpecimen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iSpecimen and other key companies, straight to your email.

About iSpecimen

iSpecimen (NASDAQ:ISPC), Inc. operates a digital marketplace designed to connect life sciences researchers with human biospecimens and related clinical information. Its platform helps researchers identify and request samples such as blood, tissue, and other biological materials from hospitals, laboratories, biobanks, and other healthcare or research organizations.

The company’s services support biospecimen sourcing, patient and donor matching, inventory discovery, order management, and sample logistics. iSpecimen serves pharmaceutical and biotechnology companies, diagnostic developers, academic institutions, and other organizations conducting biomedical research and developing new therapies and tests.

Founded in 2009, iSpecimen has focused on using software to streamline access to traditionally fragmented biospecimen inventories. Its marketplace is intended to support research across multiple disease areas and geographic regions, subject to the availability of participating providers and applicable regulatory and privacy requirements.

View iSpecimen Profile